Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Currently, molecular markers are not used when determining the prognosis and treatment strategy for patients with hepatocellular carcinoma (HCC). In the present study, we proposed that the identification of common pro‐oncogenic pathways in primary tumors (PT) and adjacent non‐malignant tissues (AT) typically used to predict HCC patient risks may result in HCC biomarker discovery. We examined the genome‐wide mRNA expression profiles of paired PT and AT samples from 321 HCC patients. The workflow integrated differentially expressed gene selection, gene ontology enrichment, computational classification, survival predictions, image analysis and experimental validation methods. We developed a 24‐ribosomal gene‐based HCC classifier (RGC), which is prognostically significant in both PT and AT. The RGC gene overexpression in PT was associated with a poor prognosis in the training (hazard ratio = 8.2, P = 9.4 × 10−6) and cross‐cohort validation (hazard ratio = 2.63, P = 0.004) datasets. The multivariate survival analysis demonstrated the significant and independent prognostic value of the RGC. The RGC displayed a significant prognostic value in AT of the training (hazard ratio = 5.0, P = 0.03) and cross‐validation (hazard ratio = 1.9, P = 0.03) HCC groups, confirming the accuracy and robustness of the RGC. Our experimental and bioinformatics analyses suggested a key role for c‐MYC in the pro‐oncogenic pattern of ribosomal biogenesis co‐regulation in PT and AT. Microarray, quantitative RT‐PCR and quantitative immunohistochemical studies of the PT showed that DKK 1 in PT is the perspective biomarker for poor HCC outcomes. The common co‐transcriptional pattern of ribosome biogenesis genes in PT and AT from HCC patients suggests a new scalable prognostic system, as supported by the model of tumor‐like metabolic redirection/assimilation in non‐malignant AT. The RGC, comprising 24 ribosomal genes, is introduced as a robust and reproducible prognostic model for stratifying HCC patient risks. The adjacent non‐malignant liver tissue alone, or in combination with HCC tissue biopsy, could be an important target for developing predictive and monitoring strategies, as well as evidence‐based therapeutic interventions, that aim to reduce the risk of post‐surgery relapse in HCC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
arrayQualityMetrics—a bioconductor package for quality assessment of microarray data
Kauffmann, A., Gentleman, R., & Huber, W. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btn647 · Cited by 946 · cited 3×
“, 2012) that passed the same microarray quality assessment (Kauffmann et al., 2009).”
BackgroundMethodResection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879 · cited 1×
“Notable disease treatment challenges include the high heterogeneity of the primary tumor (PT) and the pathophysiological status of the adjacent non-malignant tissue (AT), which affects 70% of patients after resection or local ablation (Llovet et al., 2005).”
BackgroundGoldstein, S. D., Trucco, M., Guzman, W. B., Hayashi, M., & Loeb, D. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8522 · Cited by 78 · cited 1×
“…demonstrated to be a pathologically essential and strong prognostic factor in several studies, including ours, DKK1 could be a potential candidate for a future preclinical study of anti-DKK1 therapy in HCC, as described for myeloma (Fulciniti et al., 2009) and osteosarcoma (Goldstein et al., 2016).”
Background
Metadata
- Authors
- Grinchuk, O. V., Yenamandra, S. P., Iyer, R., Singh, M., Lee, H. K., Lim, K. H., Chow, P. K., & Kuznetsov, V. A.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2017-12-12
- Volume
- 12
- Issue
- 1
- Pages
- 89-113
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2767965002
- Cited by
- 236
- References
- 6
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. https://app.cochat.ai/papers/10.1002/1878-0261.12153
- The paper
- Grinchuk, O. V., Yenamandra, S. P., Iyer, R., Singh, M., Lee, H. K., Lim, K. H., Chow, P. K., & Kuznetsov, V. A. (2018). Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.12153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.